These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 21036891)

  • 1. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circ Heart Fail; 2011 Jan; 4(1):8-17. PubMed ID: 21036891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.
    Lewis GD; Lachmann J; Camuso J; Lepore JJ; Shin J; Martinovic ME; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Jan; 115(1):59-66. PubMed ID: 17179022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
    Westermann D; Becher PM; Lindner D; Savvatis K; Xia Y; Fröhlich M; Hoffmann S; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2012 Nov; 107(6):308. PubMed ID: 23117837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R
    Eur J Heart Fail; 2012 Jan; 14(1):82-90. PubMed ID: 22067410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure.
    Cvelich RG; Roberts SC; Brown JN
    Ann Pharmacother; 2011 Dec; 45(12):1551-8. PubMed ID: 22116990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of L-arginine on the Minnesota Living with Heart Failure Questionnaire quality-of-life score in patients with chronic systolic heart failure.
    Fontanive P; Saponati G; Iurato A; Volterrani C; Boni A; Piccioni L; Dini FL;
    Med Sci Monit; 2009 Dec; 15(12):CR606-11. PubMed ID: 19946230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial.
    Andersen MJ; Ersbøll M; Axelsson A; Gustafsson F; Hassager C; Køber L; Borlaug BA; Boesgaard S; Skovgaard LT; Møller JE
    Circulation; 2013 Mar; 127(11):1200-8. PubMed ID: 23406672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
    Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
    Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
    Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging.
    Giannetta E; Isidori AM; Galea N; Carbone I; Mandosi E; Vizza CD; Naro F; Morano S; Fedele F; Lenzi A
    Circulation; 2012 May; 125(19):2323-33. PubMed ID: 22496161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction.
    Badano LP; Albanese MC; De Biaggio P; Rozbowsky P; Miani D; Fresco C; Fioretti PM
    J Am Soc Echocardiogr; 2004 Mar; 17(3):253-61. PubMed ID: 14981424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in left ventricular diastolic stiffness induced by physical training in patients with dilated cardiomyopathy.
    Malfatto G; Branzi G; Osculati G; Valli P; Cuoccio P; Ciambellotti F; Parati G; Facchini M
    J Card Fail; 2009 May; 15(4):327-33. PubMed ID: 19398081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of sildenafil in the therapeutic management of heart failure.
    Guazzi M; Samaja M; Arena R; Vicenzi M; Guazzi MD
    J Am Coll Cardiol; 2007 Nov; 50(22):2136-44. PubMed ID: 18036451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of sildenafil on haemodynamic parameters of pulmonary circulation and physical capacity in patients with systolic chronic heart failure with secondary severe pulmonary hypertension].
    Josiak K; Inorowicz E; Petruk-Kowalczyk J; Kremis E; Wilczyński J; Zymliński R; Biegus J; Jankowska E; Banasiak W; Ponikowski P
    Kardiol Pol; 2011; 69(5):517-9. PubMed ID: 21594853
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
    Behling A; Rohde LE; Colombo FC; Goldraich LA; Stein R; Clausell N
    J Card Fail; 2008 Apr; 14(3):189-97. PubMed ID: 18381181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity.
    Kim KH; Kim YJ; Ohn JH; Yang J; Lee SE; Lee SW; Kim HK; Seo JW; Sohn DW
    Circulation; 2012 Mar; 125(11):1390-401. PubMed ID: 22319106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and hemodynamic cardiac determinants of exercise capacity in patients with systolic heart failure.
    Hummel YM; Bugatti S; Damman K; Willemsen S; Hartog JW; Metra M; Sipkens JS; van Veldhuisen DJ; Voors AA
    Am J Cardiol; 2012 Nov; 110(9):1336-41. PubMed ID: 22818784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
    Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
    J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients.
    Guimaraes GV; d'Avila VM; Pires P; Bacal F; Stolf N; Bocchi E
    Transplant Proc; 2007 Dec; 39(10):3142-9. PubMed ID: 18089340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.